| Status | Suspended |
| Decision | Selected |
| Process | TA |
| Referral date | 01 November 2008 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 July 2010 |
The manufacturer oferlotinib has advised us that regulatory approval for this technology is not being sought. The Institute has therefore decided to suspend this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: (cathryn.hall@nice.org.uk). |
| 13 August | Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early August 2010. The deadline for submissions is expectedin approximately early October 2010. |
For further information on our processes and methods, please see our CHTE processes and methods manual